Sign in

Private company

Prometheus Biosciences, Inc.

Prometheus Biosciences, Inc. is an American pharmaceutical preparations company, incorporated in Delaware.1 It is headquartered in San Diego, California.1

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersSan Diego, California1
  • Incorporated inDE2
  • Business address3050 Science Park Road, San Diego, Ca 921212
  • Filer categoryLarge accelerated filer2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-2141.0%Operating margin3
-2081.8%Net margin3
117.6%Revenue growth, 20223
-21.0%Return on equity3
-$126.0MFree cash flow3

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development100¢$112.8M

Out of $6.8M in revenue.3 The company lost money this year.

Financial statements

Revenue3$6.8M in 2022+454% since 2020
0$2.0M$4.0M$6.0M$8.0M2020: $1.2M$1.2M20202021: $3.1M$3.1M2021+155%2022: $6.8M$6.8M2022+118%
Operating income3-$145.8M in 2022+403% since 2020
-$150.0M-$100.0M-$50.0M02020: -$29.0M-$29.0M20202021: -$87.8M-$87.8M2021+203%2022: -$145.8M-$145.8M2022+66%
Net income3-$141.8M in 2022+282% since 2020
-$150.0M-$100.0M-$50.0M02020: -$37.1M-$37.1M20202021: -$90.2M-$90.2M2021+143%2022: -$141.8M-$141.8M2022+57%
Fiscal year2019202020212022
Revenue$1.2M3$3.1M3$6.8M3
Research and development$19.1M3$62.4M3$112.8M3
Operating expenses$90.9M3$152.6M3
Operating income-$29.0M3-$87.8M3-$145.8M3
Interest$2.1M3$861.0K3
Income tax$03$03
Net income-$37.1M3-$90.2M3-$141.8M3
Earnings per share-$24.783-$2.883-$3.493
Earnings per share (diluted)-$24.783-$2.883-$3.493
Shares (weighted, basic)31.3M shares340.6M shares3
Shares (weighted, diluted)31.3M shares340.6M shares3

Compare Prometheus Biosciences, Inc. with another company

Corporate structure

Prometheus Biosciences, Inc. is part of a group headed by Merck & Co.. 347 entities, 69 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Prometheus Biosciences, Inc.

  • Merck & Co. Rahway, New Jersey, United States
    • MSD Sharp & Dohme GmbH München, Germany
    • Prometheus Biosciences, Inc. San Diego, California
    • Merck (Japan) Subsidiary · Tokyo, Japan
    • Merck Sharp & Dohme Latvija, SIA Subsidiary · Riga, Latvia
    • Merck Sharp & Dohme, UAB Subsidiary · Vilnius, Lithuania
    • MSD (Netherlands) Subsidiary · Amsterdam, Netherlands
    • MSD Norway AS Subsidiary · Drammen, Norway
    • Sirna Therapeutics Subsidiary · San Francisco
    • 7728026 Canada Inc. Subsidiary · Canada
    • Abceutics, Inc. Subsidiary · Delaware, United States
    • Abmaxis Inc. Subsidiary · Delaware, United States
    • Acceleron Pharma Inc. Subsidiary · Delaware, United States
    • Afferent Pharmaceuticals, Inc. Subsidiary · Delaware, United States
    • Agrident GmbH Subsidiary · Germany
    • Allflex (China) Intelligent Technology Co. Ltd. Subsidiary · China
    • Allflex Argentina S.A. Subsidiary · Argentina
    • Allflex Australia Pty. Ltd. Subsidiary · Australia
    • Allflex Dan-Mark ApS Subsidiary · Denmark
    • Allflex Europe S.A.S. Subsidiary · France
    • Allflex Group Germany GmbH Subsidiary · Germany
    • ALLFLEX INDIA PRIVATE LIMITED Subsidiary · Gurugram, India
    • Allflex Maroc S.A.R.L. Subsidiary · Morocco
    • Allflex New Zealand Subsidiary · New Zealand
    • Allflex Polska Spolka z ograniczona odpowiedzialnoscia Subsidiary · Poland
    • Allflex Romania S.R.L. Subsidiary · Romania
    • and 316 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Prometheus Biosciences, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$4.9M3 Dec 31, 2022$1.9M3 Dec 31, 2021+165.0%
Accumulated depreciation$1.0M3 Dec 31, 2022$407.0K3 Dec 31, 2021+154.5%
Property and equipment, net$3.9M3 Dec 31, 2022$1.4M3 Dec 31, 2021+167.9%
Operating-lease assets (leased space)$27.8M3 Dec 31, 2022

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$292.4M3 Dec 31, 2022$257.3M3 Dec 31, 2021+13.7%
Marketable securities, current$403.3M3 Dec 31, 2022
Debt securities available for sale$652.3M3 Dec 31, 2022

Leadership

Who has led Prometheus Biosciences, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Mark C. McKenna2021–2023

Chair

  1. Mark C. McKenna2021–2023

President

  1. Mark C. McKenna2021–2023

Chief financial officer

  1. Keith W. Marshall2021–2023

Chief operating officer

  1. Mark Stenhouse2021–2023
2025
Board members and other officers (11)

Former names

  • Precision IBD, Inc.Oct 10, 2017 to Jul 15, 20192

Timeline

  1. Jun 16, 20238-K Completed an acquisition or sale; Listing notice or transfer; Change to shareholders' rights22
  2. Jun 15, 20238-K Shareholder vote23
  3. May 23, 20238-K Other events24
  4. May 9, 20238-K Results of operations25
  5. Apr 17, 20238-K Entered a material agreement; Regulation FD disclosure26
  6. Mar 10, 20238-K Regulation FD disclosure27
  7. Feb 28, 20238-K Results of operations28
  8. Dec 9, 20228-K Other events29
  9. Dec 7, 20228-K Other events30
  10. Nov 9, 20228-K Results of operations31
  11. Oct 3, 20228-K Other events32
  12. Aug 11, 20228-K Results of operations33
  13. Mar 11, 2021New chief executive Mark C. McKenna becomes CEO8

Calendar

When it reported results

  1. May 9, 2023Reported quarterly or annual results25
  2. Feb 28, 2023Reported quarterly or annual results28
  3. Nov 9, 2022Reported quarterly or annual results31
  4. Aug 11, 2022Reported quarterly or annual results33
  5. May 12, 2022Reported quarterly or annual results34
  6. Mar 9, 2022Reported quarterly or annual results35
  7. Nov 12, 2021Reported quarterly or annual results36

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

115 filings to the SEC since October 2021: 3 annual reports, 5 quarterly reports, 20 major events, 54 insider forms, 17 large holders, 16 other. The latest 20:

  1. Jun 27, 202315-12G EDGAR
  2. Jun 16, 2023S-8 POS EDGAR
  3. Jun 16, 2023S-8 POS EDGAR
  4. Jun 16, 2023POSASR EDGAR
  5. Jun 16, 20238-K EDGAR
  6. Jun 16, 20234 FORM 4 SUBMISSION EDGAR
  7. Jun 16, 20234 FORM 4 SUBMISSION EDGAR
  8. Jun 16, 20234 FORM 4 SUBMISSION EDGAR
  9. Jun 16, 20234 FORM 4 SUBMISSION EDGAR
  10. Jun 16, 20234 FORM 4 SUBMISSION EDGAR
  11. Jun 16, 20234 FORM 4 SUBMISSION EDGAR
  12. Jun 16, 20234 FORM 4 SUBMISSION EDGAR
  13. Jun 16, 20234 FORM 4 SUBMISSION EDGAR
  14. Jun 16, 20234 FORM 4 SUBMISSION EDGAR
  15. Jun 16, 20234 FORM 4 SUBMISSION EDGAR
  16. Jun 15, 20238-K EDGAR
  17. Jun 6, 2023DEFA14A EDGAR
  18. Jun 2, 20234 FORM 4 SUBMISSION EDGAR
  19. Jun 2, 20234 FORM 4 SUBMISSION EDGAR
  20. Jun 2, 20234 FORM 4 SUBMISSION EDGAR

The 115 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

12 open-market trades by officers, directors and large owners since October 2021: 0 buys and 12 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 5, 2023Marshall Keith WChief Financial OfficerSale10,000$108.42$1.1MForm 4
Mar 15, 2023McKenna Mark C.Chairman, President and CEOSale25,000$116.14$2.9MForm 4
Mar 8, 2023Cedars Sinai Intellectual Property Co10% ownerSale865,000$114.59$99.1MForm 4
Mar 6, 2023Marshall Keith WChief Financial OfficerSale10,000$122.13$1.2MForm 4
Mar 3, 2023McKenna Mark C.Chairman, President and CEOSale10,620$125.13$1.3MForm 4
Mar 1, 2023McKenna Mark C.Chairman, President and CEOSale700$125.26$87.7KForm 4
Feb 17, 2023McKenna Mark C.Chairman, President and CEOSale13,680$125.10$1.7MForm 4
Feb 16, 2023McKenna Mark C.Chairman, President and CEOSale25,000$119.87$3.0MForm 4
Feb 15, 2023Marshall Keith WChief Financial OfficerSale5,000$119.38$596.9KForm 4
Feb 15, 2023McKenna Mark C.Chairman, President and CEOSale25,000$119.42$3.0MForm 4
Jan 17, 2023Marshall Keith WChief Financial OfficerSale5,000$119.00$595.0KForm 4
Jan 17, 2023McKenna Mark C.Chairman, President and CEOSale25,000$118.99$3.0MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Prometheus Biosciences, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARPrometheus Biosciences, Inc.1
  • CIK0001718852
  • Employer ID (EIN)81-42826531
  • Filer statusLarge accelerated filer1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address3050 Science Park Road, San Diego, CA 921211
  • Phone(858) 422-43001
  • Shares outstanding47,809,476 as of May 1, 20236
  • Public float$872.7M as of Jun 30, 202245
  • On EDGAR sinceOct 10, 20171
  • Filings189 in all: 4 (68), 8-K (26), 3 (20), SC 13G (11), SC 13G/A (10), 10-Q (7), CORRESP (4), D (4)1
    All 36 form types

    DEFA14A (4), UPLOAD (3), 10-K (2), 424B5 (2), S-1/A (2), S-8 (2), S-8 POS (2), SEC STAFF LETTER (2), 10-K/A (1), 144 (1), 15-12G (1), 25-NSE (1), 3/A (1), 424B4 (1), 8-A12B (1), CERT (1), D/A (1), DEF 14A (1), DEFM14A (1), DRS (1), DRS/A (1), DRSLTR (1), EFFECT (1), POSASR (1), PREM14A (1), S-1 (1), S-1MEF (1), S-3ASR (1)

  • Latest filingsAnnual report (10-K) Feb 28, 2023
    Quarterly report (10-Q) May 9, 2023
    Proxy statement (DEF 14A) Apr 1, 2022
    Latest 8-K (8-K) Jun 16, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
    SEC EDGAROther events
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
    SEC EDGAROther events
  30. 30
    SEC EDGAROther events
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45